Novel quadrivalent meningococcal A, C, W-135 and y glycoconjugate vaccine for the broader protection of adolescents and adults

Future Microbiology

Volumn 5, Issue 11, 2010, Pages 1629-1640

  Pace, David ^a  

^a MATER DEI HOSPITAL   (Malta)

Author keywords

glycoconjugate meningococcal vaccine; MenACWY CRM; Meningococcal meningitis

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE; MENINGITIS VACCINE; MENINGOCOCCUS VACCINE; NIMENRIX; PLACEBO; UNCLASSIFIED DRUG; WART VIRUS VACCINE;

ARTHRALGIA; ARTICLE; CANADA; CHILL; CLINICAL TRIAL; DIPHTHERIA; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; ERYTHEMA; EUROPE; FEVER; HUMAN; IMMUNITY; INJECTION SITE PAIN; JUVENILE; MALAISE; MYALGIA; NAUSEA; NEISSERIA MENINGITIDIS; PERTUSSIS; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; TETANUS; UNITED STATES; VACCINATION;

ADOLESCENT; ADULT; AGED; CANADA; CHILD; CLINICAL TRIALS AS TOPIC; EUROPE; HUMANS; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL INFECTIONS; MENINGOCOCCAL VACCINES; MIDDLE AGED; NEISSERIA MENINGITIDIS; SEPSIS; UNITED STATES; VACCINATION; VACCINES, CONJUGATE; YOUNG ADULT;

NEISSERIA MENINGITIDIS;

EID: 78650198030     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/fmb.10.137     Document Type: Article

References (42)

1. Trotter CL, Chandra M, Cano R et al.: A surveillance network for meningococcal disease in Europe. FEMS Microbiol. Rev. 31(1), 27-36 (2007).
2. Bilukha OO, Rosenstein N; National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC): Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 54(RR-7), 1-21 (2005).
3. Harrison LH, Pass MA, Mendelsohn AB et al.: Invasive meningococcal disease in adolescents and young adults. JAMA 286(6), 694-699 (2001).
4. Mayer LW, Reeves M W, Al-Hamdan N et al.: Outbreak of W135 meningococcal disease in 2000: not emergence of a new W135 strain but clonal expansion within the electophoretic type-37 complex. J. Infect. Dis. 185(11), 1596-1605 (2002).
5. Centers for Disease Control and Prevention (CDC): Updated recommendation from the Advisory Committee on Immunization Practices (ACIP) for revaccination of persons at prolonged increased risk for meningococcal disease. MMWR Morb. Mortal Wkly Rep. 58(37), 1042-1043 (2009).
6. Kirsch EA, Barton RP, Kitchen L, Giroir BP: Pathophysiology, treatment and outcome of meningococcemia: a review and recent experience. Pediatr. Infect. Dis. J. 15, 967-979 (1996).
7. Teyssou R, Muros-Le Rouzic E: Meningitis epidemics in Africa: a brief overview. Vaccine 25(Suppl. 1), A3-A7 (2007).
8. Broome CV, Rugh MA, Yada AA et al.: Epidemic group C meningococcal meningitis in Upper Volta, 1979. Bull. World. Health Organ. 61(2), 325-330 (1983).
9. Mutonga DM, Pimentel G, Muindi J et al.: Epidemiology and risk factors for serogroup X meningococcal meningitis during an outbreak in western Kenya, 2005-2006. Am. J. Trop. Med. Hyg. 80(4), 619-624 (2009).
10. Reingold AL, Broome CV, Hightower AW et al.: Age-specific differences in duration of clinical protection after vaccination with meningococcal polysaccharide A vaccine. Lancet 2(8447), 114-118 (1985).
11. Granoff DM, Pollard AJ: Reconsideration of the use of meningococcal polysaccharide vaccine. Pediatr. Infect. Dis. J. 26(8), 716-722 (2007).
12. Mond JJ, Kokai-Kun JF: The multifunctional role of antibodies in the protective response to bacterial T cell-independent antigens. Curr. Top. Microbiol. Immunol. 319, 17-40 (2008).
13. Maiden MC, Ibarz-Pavón AB, Urwin R et al.: Impact of meningococcal serogroup C conjugate vaccines on carriage and herd immunity. J. Infect. Dis. 197(5), 737-743 (2008).
14. Campbell H, Borrow R, Salisbury D, Miller E: Meningococcal C conjugate vaccine: the experience in England and Wales. Vaccine 24(27 Suppl. 2), B20-B29 (2009).
15. Centers for Disease Control and Prevention (CDC): Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP) 2010. MMWR 59(9), 273 (2010).
16. National Advisory Committee on Immunization (NACI): Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. An Advisory Committee Statement (ACS). Can. Commun. Dis. Rep. 33(ACS-3), 1-23 (2007).
17. Ostergaard L, Lebacq E, Poolman J, Maechler G, Boutriau D: Immunogenicity reactogenicity and persistence of meningococcal A, C, W-135 and Y-tetanus toxoid candidate conjugate (MenACWY-TT) vaccine formulations in adolescents aged 15-25 years. Vaccine 27(1), 161-168 (2009).
18. Knuf M, Kieninger-Baum D, Habermehl P et al.: A dose-range study assessing immunogenicity and safety of one dose of a new candidate meningococcal serogroups A, C, W-135, Y tetanus toxoid conjugate (MenACWY-TT) vaccine administered in the second year of life and in young children. Vaccine 28(3), 744-753 (2010).
19. Vesikari T, Karvonen A, Korhonen T, Poolman J, Boutriau D: Immunogenicity of one dose of an investigational meningococcal tetravalent tetanus-toxoid conjugate (ACWY-TT) vaccine in 2-10 year olds. Presented at: Proceedings of the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases-ESPID. Brussels, Belgium, 9-13 June 2009.
20. Bardotti A, Averani G, Berti F et al.: Physicochemical characterisation of glycoconjugate vaccines for prevention of meningococcal diseases. Vaccine 26(18), 2284-2296 (2008).
21. Lemercinier X, Jones C: Full 1H NMR assignment and detailed O-acetylation patterns of capsular polysaccharides from Neisseria meningitidis used in vaccine production. Carbohydr. Res. 296, 83-96 (1996).
22. Goldschneider I, Gotschlich EC, Artenstein MS: Human immunity to the meningococcus. I. The role of humoral antibodies. J. Exp. Med. 129(6), 1307-1326 (1969).
23. Andrews N, Borrow R, Miller E: Validation of serological correlate of protection for meningococcal C conjugate vaccine by using effcacy estimates from postlicensure surveillance in England. Clin. Diagn. Lab. Immunol. 10(5), 780-786 (2003).
24. Trotter CL, Andrews NJ, Kaczmarski EB, Miller E, Ramsay ME: Effectiveness of meningococcal serogroup C conjugate vaccine 4 years after introduction. Lancet 364(9431), 365-367 (2004).
25. Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM: A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr. Infect. Dis. J. 28(2), 86-91 (2009).
26. Jackson LA, Baxter R, Reisinger K et al.: V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin. Infect. Dis. 49(1), e1-e10 (2009).
27. Findlow H, Plikaytis BD, Aase A et al.: Investigation of different group A immunoassays following one dose of meningococcal group A conjugate vaccine or A/C polysaccharide vaccine in adults. Clin. Vaccine Immunol. 16(7), 969-977 (2009).
28. Gill CJ, Anemona A, Ciavarro G, DeTora L, Bedell L, Dull P: Persistence of bactericidal activity in adolescents 12 and 21 months following receipt of meningococcal vaccines against serogroup A, C, W-135, and Y. Presented at: Proceedings of the 28th Annual Meeting of the European Society of Paediatric Infectious Diseases (ESPID). Nice, France, Poster Abstract, 4-8 May 2010.
29. Gasparini R, Conversano M, Bona G et al.: Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin. Vaccine Immunol. 17(4), 537-544 (2010).
30. Arguedas A, Soley C, Loaiza C et al.: Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 28(18), 3171-3179 (2010).
31. Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM: Quadrivalent meningococcal vaccination of adults: Phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin. Vaccine Immunol. 16(12), 1810-1815 (2009).
32. Stamboulian D, Lopardo G, Lopez P et al.: Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY- CRM, compared with licensed vaccines in adults in Latin America. Int J. Infect. Dis. 14(10), E868-E875 (2010).
33. Health Canada. Drugs and Health products. Notice of Decision for Menveo. Health Canada, ON, Canada, 23 June 2010.
34. Lorick SA, Fishbein D, Weintraub E et al.: Uptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: demand, supply and seasonality. BMC Infect. Dis. 9, 175 (2009).
35. National Advisory Committee on Immunization (NACI). An update on the invasive meningococcal disease and meningococcal vaccine conjugate recommendations. An Advisory Committee Statement (ACS). Can. Commun. Dis Rep. 35(ACS-3), 1-40 (2009).
36. Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM: Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 28(3), 657-663 (2010).
37. Snape MD, Perrett KP, Ford KJ et al.: Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 299(2), 173-184 (2009).
38. Perrett KP, Snape MD, Ford KJ et al.: Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr. Infect. Dis. J. 28(3), 186-193 (2009).
39. Snape MD, Kelly DF, Lewis S et al.: Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 336(7659), 1487-1491 (2008).
40. Keyserling H, Papa T, Koranyi K et al.: Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents. Arch. Pediatr. Adolesc. Med. 159(10), 907-913 (2005).
41. Trotter CL, Gay NJ, Edmunds WJ: Dynamic models of meningococcal carriage, disease, and the impact of serogroup C conjugate vaccination. Am. J. Epidemiol. 162(1), 89-100 (2005).
42. De Wals P, Trottier P, Pépin J: Relative effcacy of different immunization schedules for the prevention of serogroup C meningococcal disease: a model-based evaluation. Vaccine 24(17), 3500-3504 (2006).